This study will investigate the use of a new medicine called AMT-151 which may be used in the future as a possible treatment for advanced solid tumours.

Trial Status
Trial Phase
Phase 1 Drug Trial
Registry Listing
ERM Project ID
Trial contact details
Contact Person
Caitlin Bennett
What you need to know

Who can take part?

Patients with advanced solid tumour and standard therapy has either been exhausted or is not available.

What is involved for you?

You will receive the study drug once every 3 weeks through intravenous (IV) infusion, which will take approximately one hour. You will be required to attend the clinic at least every  week during treatment for a physical assessment, blood tests, ECGs and ongoing assessments. You will also receive ongoing tumour assessments via scans.

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.



Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.



Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|